News

Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...
Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperforms
Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...
Pharmaceutical Technology on MSN6d
Madrigal poised to enter European MASH market after CHMP endorsement
Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...
Fierce Pharma2h
Incyte waves goodbye to longtime CEO Hervé Hoppenot as new appointment raises M&A hopes
After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...
Insider Monkey2d
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic ...
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval
Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease ...
EU regulator backs conditional authorisation for Madrigal's liver disease drug
The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...
Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...